Atropine vs Orthokeratology for Myopia Control: A Complete Parent's Guide

When an optometrist first recommends myopia control treatment for a child, most parents hear two names repeated more than any others: atropine and orthokeratology. Both are evidence-based interventions that slow the progression of myopia. Both are widely used in Singapore and across East Asia. And the question of which to choose — or whether to combine them — is one that families grapple with every day.

This guide walks through how each treatment works, what the research actually shows about their effectiveness, the practical differences in side effects and daily life, and how clinicians in Singapore typically approach the decision.

How Atropine Works

Atropine is a muscarinic antagonist — a class of drug that blocks certain receptors in the eye. Applied as a daily eye drop, it has been used to slow myopia progression since the 1970s. Singapore's National Eye Centre (SNEC) has used atropine for childhood myopia for more than two decades, making Singapore one of the most experienced centres globally for this treatment.

The precise mechanism by which atropine slows eye growth is not fully understood. Current evidence suggests it acts on receptors in the retina and sclera to inhibit the biochemical signals that drive axial elongation — the physical lengthening of the eyeball that causes myopia to worsen. What is clear from multiple large randomised trials is that it works.

Atropine is available in several concentrations. The landmark ATOM (Atropine for Treatment of Myopia) studies, conducted at SNEC, established that 0.01% concentration offers meaningful myopia control with a dramatically improved side effect profile compared to higher doses. Clinical practice in Singapore today most commonly starts at 0.01%, escalating to 0.025% or 0.05% if progression continues.

What Atropine Treatment Looks Like Day-to-Day

A child using atropine applies one drop to each eye each night before bed. The routine takes under a minute and requires no additional equipment. The drops are typically prescribed by an ophthalmologist or optometrist and dispensed by a pharmacy or eye clinic. Children do not notice any immediate change in their vision after applying the low-dose formulation overnight, and they wake up with normal daytime vision.

How Orthokeratology Works

Orthokeratology (Ortho-K) takes an entirely different approach. Instead of a pharmacological intervention, it uses specially designed rigid contact lenses worn overnight while the child sleeps. These lenses temporarily reshape the cornea — the clear front surface of the eye — so that when the child wakes up and removes the lenses, they can see clearly throughout the day without any glasses or contact lenses.

The reshaping effect lasts approximately one to two days, which is why lenses must be worn every night (or every other night in some cases) to maintain the effect. If lenses are stopped, the cornea returns to its original shape within a few days and myopia returns.

Beyond providing daytime freedom from glasses, Ortho-K also slows myopia progression. The current understanding is that the modified corneal shape creates peripheral defocus — a refractive pattern that inhibits the retinal signals driving axial elongation. Multiple clinical trials have confirmed that this mechanism meaningfully slows eye growth in children.

What Ortho-K Treatment Looks Like Day-to-Day

Ortho-K requires a professional fitting process, typically involving corneal topography and precise measurements. The lenses are inserted at bedtime and removed in the morning. Lens care involves rinsing, cleaning with a multipurpose solution, and storing lenses in a case. Children and parents must be comfortable handling rigid lenses — this is often the main practical barrier for younger children.

Follow-up appointments are more frequent than with atropine, particularly in the first three to six months as the prescription is optimised.

Comparing Efficacy: What the Evidence Shows

This is the question parents most want answered: which treatment actually works better? The honest answer is that, at standard dosing, atropine (0.01%) and orthokeratology perform at roughly similar levels — both significantly better than conventional spectacles alone.

Here is a summary of key findings from peer-reviewed research:

Treatment	Axial Elongation at 2 Years	Approximate Reduction vs Spectacles
Single-vision spectacles (control)	~0.65 mm	—
Orthokeratology	~0.41 mm	~40–50%
0.01% Atropine	~0.12 mm axial length benefit vs control	~15–20%
0.025% Atropine	~0.31 mm cumulative benefit at 3 years	~30–35%
0.05% Atropine	~0.55 mm cumulative benefit at 3 years	~45–55%
0.04% Atropine (emerging)	Superior to 0.01%; difference of ~0.18 mm	Higher than 0.01% dose
Ortho-K + 0.01% Atropine	Additional ~0.12 mm benefit vs Ortho-K alone	Strongest current evidence

Sources: IMI Interventions Report 2025; ATOM2 study; LORIC study; ROMIO study; PubMed RCT data.

A few important points about this table. First, the LORIC and ROMIO studies — conducted in Hong Kong — are among the most-cited Ortho-K trials and showed 43% and 63% reduction in progression respectively compared to control groups wearing single-vision spectacles. The range reflects differences in study populations and follow-up periods.

Second, a 2025 randomised clinical trial published in JAMA Ophthalmology directly compared 0.04% atropine, 0.01% atropine, and orthokeratology in children aged 8–15. The 0.04% concentration outperformed the other two options in reducing axial elongation, though it carried a higher incidence of photophobia. At standard 0.01% dosing, atropine and orthokeratology performed comparably.

Third, the strongest efficacy by far comes from combination therapy, covered in more detail below.

Side Effects and Practical Considerations

Atropine Side Effects

At 0.01% concentration, the most common side effect is mild light sensitivity and slightly reduced ability to focus up close — effects so minor that most children and parents report not noticing them at all. At higher concentrations (0.025%, 0.05%), these effects become more pronounced. Some children need UV-protective spectacles or sunglasses in bright outdoor settings when on higher-dose atropine.

A small proportion of children experience an allergic reaction to the preservatives in the eye drop formulation. Preservative-free formulations are available but typically more expensive. There is no evidence of long-term harm to the eye from low-dose atropine at currently used concentrations, based on decades of clinical use in Singapore and elsewhere in Asia.

One consideration specific to higher doses is the rebound effect: when 0.1% atropine is stopped abruptly, myopia can progress faster than it would have without treatment. The evidence for significant rebound at 0.01% is limited, but most clinicians taper rather than stop abruptly as a precaution.

Orthokeratology Side Effects

The safety profile of Ortho-K is generally good under proper supervision, but it carries risks that atropine does not. Between 10% and 20% of children experience minor adverse events over the course of a year — typically mild corneal staining, lens discomfort, or mild infection — most of which resolve without permanent effects.

The more serious risk is microbial keratitis — a corneal infection that can, in rare cases, cause vision loss. The incidence in published studies is estimated at approximately 7–8 per 10,000 patient-years of Ortho-K wear, which is low but not negligible. The risk is substantially reduced with correct lens hygiene, regular professional review, and prompt attention to any eye redness, pain, or blurred vision.

Because Ortho-K involves overnight lens wear by children, parents need to be confident that their child has good hygiene habits and can communicate any eye discomfort promptly. A child who rubs their eyes, sleeps in inconsistent positions, or is resistant to the lens-handling routine is a practical concern even if they are clinically a good candidate.

Cost and Accessibility in Singapore

Cost is a real factor for most families making a long-term treatment decision.

Atropine is relatively accessible. A monthly supply of 0.01% atropine drops from a specialist clinic or compounding pharmacy in Singapore typically costs significantly less than orthokeratology. The main ongoing cost is the clinic consultation fee, which for myopia management reviews is typically every four to six months.

Orthokeratology involves higher initial outlay. The fitting process, corneal topography, and first set of lenses represent a significant upfront investment, and lenses need to be replaced periodically — typically every one to two years — as they wear and as the prescription changes. Most families should expect ongoing annual costs for replacement lenses and follow-up consultations.

Both treatments require regular professional monitoring, so neither eliminates ongoing clinic costs entirely.

For families where the financial difference is a constraint, 0.01% atropine offers a clinically meaningful intervention at a lower cost point. For families where Ortho-K's freedom from daytime glasses is important — particularly for children active in sports — the additional cost may represent good value.

Who Is Each Treatment Better Suited For?

There is no single right answer, and the appropriate choice depends on the individual child. Clinicians in Singapore typically consider the following:

Atropine may be preferred when:

For younger children or those who are not yet ready for overnight lens handling, atropine is typically the first-line recommendation. It is also the default choice when simplicity and lower cost are priorities.

The child is younger (under 8) and not yet ready to manage contact lenses
Parents prefer a simple, low-maintenance routine
The degree of myopia is relatively low (under -3.00 D) and stable
There are concerns about corneal infection risk or lens hygiene compliance
Cost is a significant consideration

Orthokeratology may be preferred when:

Ortho-K suits older children who can manage the lens-handling routine and for whom the freedom from daytime glasses is a meaningful quality-of-life benefit — particularly those involved in sport or who find spectacles uncomfortable.

The child is 8 or older and capable of safe lens handling
Freedom from daytime glasses or contact lenses is important (sports, aesthetics)
Parents have concerns about daily eye drops (though atropine is well-tolerated)
The child's myopia level is within the treatable range for Ortho-K (typically up to -6.00 D, with limitations at higher prescriptions)

Neither is ideal when:

Some clinical factors make one or both options unsuitable regardless of preference. An experienced optometrist will identify these during the initial assessment.

A child has a high corneal astigmatism that is not suitable for standard Ortho-K designs
There is an allergy to atropine components
The family cannot commit to the follow-up schedule required for either treatment

Combination Therapy: The Best of Both Worlds

The most compelling recent development in myopia control is the evidence for combining both treatments. Multiple randomised controlled trials and meta-analyses now confirm that adding low-dose atropine to orthokeratology produces meaningfully better outcomes than either treatment alone.

A meta-analysis found that combination treatment with 0.01% atropine plus orthokeratology produced significant additional reduction in axial elongation at 6, 12, and 24 months compared to orthokeratology alone — with the combined group showing approximately 0.12 mm more reduction in axial elongation at two years.

A 2025 study in Scientific Reports went further, testing the effect of sequentially escalating atropine concentrations added to orthokeratology. Adding 0.01%, 0.025%, and 0.05% atropine to an existing Ortho-K regimen reduced annual axial elongation by 28.4%, 31.4%, and 39.4% respectively compared to orthokeratology alone — a clear dose-response relationship.

For children with fast progression, two myopic parents, or early-onset myopia (which carries the highest long-term risk), combination therapy is increasingly the standard recommendation in well-resourced myopia management programmes in Singapore and Hong Kong.

The practical implication: if your child is already on Ortho-K and progressing faster than expected, adding low-dose atropine is a clinically supported next step worth discussing with their optometrist.

How Optometrists Approach the Decision

In practice, most experienced myopia management optometrists in Singapore do not frame the atropine vs orthokeratology decision as a binary choice. The clinical decision typically involves assessing:

Rate of progression. A child progressing by more than 0.50 D per year or more than 0.25–0.30 mm of axial elongation per year is considered fast-progressing and warrants an aggressive approach — often combination therapy from the start.

Age and prescription. Younger children with higher myopia are at greater long-term risk of complications (retinal detachment, glaucoma, macular degeneration). For these children, maximising the control effect early matters most.

Lifestyle and compliance. The best treatment is the one a child will actually use consistently. A child who struggles with the Ortho-K routine but tolerates eye drops well will get more benefit from atropine.

Parental priorities. Some families strongly value daytime glasses-free vision. Others prioritise the simplest possible routine. These preferences are legitimate clinical inputs.

A structured myopia management programme typically includes axial length measurement at every visit — not just refraction — because axial length is the most direct and reliable marker of whether the treatment is working. If axial elongation continues beyond acceptable limits despite treatment, the protocol should be escalated.

Track Your Child's Progression With a Free Tool

Whether your child is currently on atropine, orthokeratology, or still in the decision phase, understanding how their myopia compares to age-matched benchmarks is a practical first step.

CarrotByte's free Myopia Progression Calculator lets you model expected progression from your child's current age and prescription across different treatment scenarios — from no treatment to orthokeratology and atropine. It takes under two minutes and requires no signup.

Try the Myopia Progression Calculator →

If you are looking for an optometrist in Singapore with specific experience in myopia management, Ortho-K fitting, or atropine therapy, the Eye Care Directory lists eye care professionals by location and specialty.

Find a myopia management specialist →

Summary

Atropine and orthokeratology are both evidence-based myopia control treatments with similar efficacy at standard dosing. Atropine (0.01%) is simpler, lower in cost, and suitable from a younger age; orthokeratology provides daytime freedom from glasses and performs well in children aged 8 and above who can manage lens care. For children with fast progression or high myopia risk, the evidence increasingly supports combining both.

The right choice depends on your child's age, prescription, rate of progression, and practical circumstances — and should be made in partnership with an experienced optometrist who measures axial length at every visit.

Atropine vs Orthokeratology for Myopia Control